The main focus of the Minna Lab is translational (“bench to bedside”) cancer research aimed at developing new ways to diagnose, prevent, and treat lung cancer based on a detailed understanding of the molecular pathogenesis of lung cancer.
The Jiang lab studies fundamental mechanisms governing how diverse cell types are generated from naive progenitor cells and how cells of different types are put together to form appropriate body structures such as limbs during embryonic development. The lab also studies how damaged cells are replenished by stem cells during tissue repair and organ regeneration in adult life. We are particularly interested in understanding how cells communicate with one another to influence their growth and fate determination and how miscommunication among different cells leads to developmental abnormality and cancer progression.
Our laboratory studies the cell biology of viral-host interactions.
The Mendell laboratory investigates fundamental aspects of post-transcriptional gene regulation, noncoding RNA regulation and function, and the roles of these pathways in normal physiology, cancer, and other diseases.
Buszczak laboratory seeks to gain new insights into mRNA translation, ribosome biogenesis and germ cell biology
Our laboratory is interested in improving treatment for patients with glioblastoma (GBM) and other cancers. We work on understanding signal transduction pathways involved in the pathogenesis of cancer. Recent work has focused on investigating mechanisms of resistance to targeted treatment in GBM and lung cancer. We are also interested in mechanisms regulating invasion in GBM.
We use genetic systems to deconstruct functions associated with the most commonly mutated genes found in human cancers.
The Brekken laboratory, located in the Hamon Center for Therapeutic Oncology Research, studies tumor-host interactions with a particular emphasis on extracellular matrix (ECM) and angiogenesis.
The Davis Lab is part of the Section of Molecular Medicine in the Department of Radiation Oncology
Our mission is to improve the care of breast cancer patients through cutting-edge translational research at the interface of clinical oncology, cancer biology, molecular genetics, and translational genomics.
